Business Context and Reporting Period
This Form 8-K Current Report was filed by Nuvation Bio Inc. on June 4, 2021, covering the event date of June 1, 2021. The company is incorporated in Delaware and trades on the New York Stock Exchange under the symbols NUVB (Class A Common Stock) and NUVB.WS (Redeemable Warrants). Nuvation Bio is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes rather than financial performance.
Material Changes
On June 1, 2021, Michelle Doig resigned from the Board of Directors of Nuvation Bio Inc. Ms. Doig had served through a transition period announced in October 2020. She was not a member of any Board committee. The company stated that her resignation was not the result of any disagreement with Nuvation Bio regarding its operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the specific disclosure of the director's departure.
Investor Verification Checklist
- Confirm the effective date of Michelle Doig's resignation (June 1, 2021).
- Verify that the resignation was not due to any disagreement with the company.
- Check subsequent filings for the appointment of a replacement director.
- Review the company's most recent 10-K or 10-Q for financial metrics not included in this 8-K.